The Publication Digests section of this Learning Zone provides simplified detail and graphical summaries of the latest published research on chronic kidney disease treatments.
The peer-reviewed article in this section describes clinical evidence for the use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in the treatment of chronic kidney disease.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors AstraZeneca, who have reviewed the content only for scientific accuracy. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.